The pharma launch market has settled the question of which tools to use. It still hasn't answered the only question that decides the launch: who is in the room. The short version: The platforms are real and the value is there, but the edge was never in owning the software. The gap nobody sells into is the person who runs it against your molecule, with authority to act. The 2027 launches that look effortless will belong to whoever put control back in the room. Six posts ago I

"AI predicts launch success" is the line everyone is selling right now. It also happens to be pointed at the easier half of the problem. The short version: Predictive launch tracking is real, and the people running pharma's biggest AI programs are still careful about the claim. Prediction works when a problem holds still, and a launch doesn't. The ROI lives in response time, not in the forecast, so buy the sensor and build the reflexes. IQVIA describes active launch tracking

Every big firm is now selling the same pharma launch. Agentic. Sense-and-respond. "Launch as a learning system." They are all describing the same thing, and none of them is in the room when it fails. The short version: The big-firm launch point of view has converged, and the platforms behind it are real. Launches still drift anyway, because the gap was never structure. It was control. The question isn't which agentic platform to buy. It's who holds the loop closed when the ma